Literature DB >> 162518

Dehydroepiandrosterone: kinetics of metabolism in normal men and women.

C E Bird, J Murphy, K Boroomand, W Finnis, D Dressel, A F Clark.   

Abstract

The single injection and constant infusion techniques were utilized to study the kinetics of dehydroepiandrosterone (DHEA) metabolism and its peripheral conversion to several other C19-steroids including C19-steroid sulfates. The MCRs (mean +/- SEM) for normal men and normal women were 1866 +/- 144 and 1901 +/- 87 liters/24 h, respectively. The single injection technique yielded values for rate constants (units) and volumes of distribution (1) as follows: K1, 42.6 +/- 7.7 for men and 37.1 +/- 5.0 for women; K2, 64.3 +/- 11.2 for men and 55.5 +/- 5.0 for women; K2, 64.3 +/- 11.2 for men and 55.5 +/- 5.0 for women; V1, 38.5 +/- 6.0 for men and 33.7 +/- 2.5 for women; V2, 30.4 +/- 7.3 for men and 27.5 +/- 9.9 for women. The constant infusion technique yielded values for the conversion ratios for the transformation of DHEA to several products: delta 5-androstene-3 beta, 17 beta-diol to DHEA of 0.10 +/- 0.01 for men and 0.16 +/- 0.03 for women, delta 4-androstenedione to DHEA of 0.04 +/- 0.01 for men and 0.07 +/- 0.02 for women, DHEA sulfate (DHEAS) to DHEA of 6.36 +/- 0.81 for men and 10.09 +/- 0.87 for women, delta 5-androstene-3 beta, 17 beta-diol sulfate to DHEA of 0.42 +/- 0.06 for men and 0.50 +/- 0.04 for women, and androsterone sulfate to DHEA of 1.11 +/- 0.13 for men and 2.06 +/- 0.18 for women. The ratios for the conversion to DHEA sulfate and androsterone sulfate were significantly higher for women than men. The plasma concentrations of DHEA were 8.50 +/- 0.95 and 8.75 +/- 1.01 ng/ml for men and women, respectively. The calculated production rates for DHEA were 16.34 +/- 2.66 and 16.19 +/- 1.78 mg/24 h for men and women, respectively. There was no sex difference in the binding of DHEA to plasma proteins and this is reflected in the lack of sex difference in the MCRs. Calculations indicate that DHEA is a major precursor of circulating delta 5-diol.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 162518     DOI: 10.1210/jcem-47-4-818

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  A high frequency missense SULT1B1 allelic variant (L145V) selectively expressed in African descendants exhibits altered kinetic properties.

Authors:  Zachary E Tibbs; Amber L Guidry; Josie L Falany; Susan A Kadlubar; Charles N Falany
Journal:  Xenobiotica       Date:  2017-02-05       Impact factor: 1.908

3.  Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition.

Authors:  Bill L Lasley; Sybil L Crawford; Gail A Laughlin; Nanette Santoro; Daniel S McConnell; Carolyn Crandall; Gail A Greendale; Alex J Polotsky; Marike Vuga
Journal:  Menopause       Date:  2011-05       Impact factor: 2.953

Review 4.  Adrenal androgens and the menopausal transition.

Authors:  Bill L Lasley; Sybil Crawford; Daniel S McConnell
Journal:  Obstet Gynecol Clin North Am       Date:  2011-09       Impact factor: 2.844

Review 5.  Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.

Authors:  Sylvie Legrain; Laurence Girard
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.

Authors:  S Dauvois; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

7.  Ovarian adrenal interactions during the menopausal transition.

Authors:  B L Lasley; S L Crawford; D S McConnell
Journal:  Minerva Ginecol       Date:  2013-12

8.  Adrenal steroids stimulate growth and progesterone receptor levels in rat uterus and DMBA-induced mammary tumors.

Authors:  P G Spinola; B Marchetti; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.